European Biotech Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares & Warrants Commencing May 6,...
04 Maggio 2021 - 11:19PM
Business Wire
European Biotech Acquisition Corp. (the “Company”) announced
today that, commencing May 6, 2021, holders of the units sold in
the Company’s initial public offering of 12,000,000 units,
completed on March 18, 2021, and the subsequent sale of an
additional 754,784 units upon partial-exercise of the underwriters’
over-allotment option, completed on May 3, 2021, may elect to
separately trade the shares of Class A ordinary shares and warrants
included in the units. Those units not separated will continue to
trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol
“EBACU,” and the shares of Class A ordinary shares and warrants
that are separated will trade on the Nasdaq under the symbols
“EBAC” and “EBACW,” respectively. Holders of units will need to
have their brokers contact Continental Stock Transfer & Trust
Company, the Company’s transfer agent, in order to separate the
units into Class A ordinary shares and warrants.
The offering was made only by means of a prospectus, copies of
which may be obtained from Credit Suisse Securities (USA) LLC,
Attn: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, North Carolina 27560, Telephone: 1-800-221-1037,
Email: usa.prospectus@credit-suisse.com or Kempen & Co U.S.A.,
Inc., attention John McGowan, Email: John.McGowan@kempenusa.com,
Telephone: 1-212-376-0132.
Credit Suisse and Kempen & Co acted as the joint
book-running managers of the offering. A registration statement
relating to the securities has been declared effective by the U.S.
Securities and Exchange Commission (the “SEC”) on March 15, 2021.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About European Biotech Acquisition Corp.
European Biotech Acquisition Corp. was formed for the purpose of
effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one
or more businesses. The Company intends to focus on identifying
promising opportunities in the life sciences industry in Europe.
The members of the management team are associated with LSP, one of
Europe’s largest and most experienced healthcare investment
firms.
Forward-Looking Statements
This press release contains statements that constitute
“forward-looking statements.” Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company’s registration statement and
preliminary prospectus for the Company’s offering filed with the
SEC. Copies of these documents are available on the SEC’s website,
www.sec.gov. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504006322/en/
Investor Eduardo Bravo Fernandez de Araoz Email:
ebac@lspvc.com
Grafico Azioni European Biotech Acquisi... (NASDAQ:EBACU)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni European Biotech Acquisi... (NASDAQ:EBACU)
Storico
Da Lug 2023 a Lug 2024